Discrimination Testing

Discrimination Testing in the context of an employer-sponsored 401(k) refers to the mandatory evaluation conducted to ensure compliance with IRS regulations, specifically to prevent highly compensated employees (HCEs) from receiving disproportionate benefits compared to non-highly compensated employees (NHCEs). The purpose of this testing is to maintain the plan's qualified status, allowing employees to enjoy tax advantages and encouraging fair distribution of retirement benefits within the organization.

The two primary types of Discrimination Testing are the Actual Deferral Percentage (ADP) test and the Actual Contribution Percentage (ACP) test. These tests assess the contributions made by both HCEs and NHCEs and compare them to ensure that the plan doesn't favor highly compensated employees excessively.

Example 1: ADP Test - If HCEs contribute significantly more to the 401(k) plan than NHCEs, the ADP test ensures that the contributions of the HCEs do not exceed certain limits based on the average contributions of NHCEs.

Example 2: ACP Test - The ACP test evaluates employer matching contributions and employer non-elective contributions. It ensures that the matching and non-elective contributions made on behalf of HCEs are reasonably proportionate to those of NHCEs.

Example 3: Corrective Measures - If the Discrimination Testing uncovers imbalances, corrective actions may be required, such as returning excess contributions to HCEs or making additional contributions to NHCEs, to bring the plan back into compliance and maintain its tax-qualified status.

In summary, Discrimination Testing plays a crucial role in promoting fairness and equitable distribution of retirement benefits within employer 401(k) plans while adhering to IRS regulations.

Next Up

Welcome to our latest release. We are excited for you to try the new features.
According to Mployer Insights’ 2026 analysis of 50,000+ employer health plans, prescription drugs account for over 25% of total benefit expenses, with Tier 4 specialty drugs driving the majority of high-cost claims. While Tier 4 copays average $123 with coinsurance requirements in 31% of plans, individual oncology therapies like Darzalex Faspro ($170,800/yr) and Keytruda ($158,200/yr) frequently exceed average individual stop-loss deductibles ($141,938). To mitigate exposure, self-funded employers are increasingly turning to independent, transparent PBM models and biosimilar substitution—which yields up to a 73% net cost reduction per patient.
Most U.S. employers now offer paid maternity leave beyond the legal minimum, but coverage varies widely once you look past the basics. According to Mployer Insights' 2026 analysis of more than 50,000 employer benefit plans, 68% of employers provide paid maternity leave on top of short-term disability, typically adding 8 extra weeks, and half now cover 100% of salary during the disability period. Support drops off from there: only 41% of employers offer paid bonding leave for non-birth parents, and advanced family-building benefits remain even less common, with just 28% covering IVF and 11% offering adoption financial assistance. The data suggests that while baseline maternity leave has become standard, more comprehensive family-building support is still the exception rather than the norm.